Physician profile
Clair Cascella
NPI 1962777169
$5,466.29
in general payments reported to CMS, 2019-2025
36 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 88% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $470 · 2021: $813 · 2022: $815 · 2023: $767 · 2024: $1,207 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,158.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.47 | 2021-2025 | Qulipta, Ubrelvy |
| Lundbeck LLC | $454.68 | 2020-2025 | Vyepti, Rexulti |
| Allergan, INC. | $431.67 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $359.70 | 2020-2022 | |
| Pfizer INC. | $353.16 | 2023-2025 | |
| Lilly USA, LLC | $283.38 | 2021-2025 | Amyvid, Kisunla, Reyvow |
| Eisai INC. | $282.40 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $265.45 | 2022-2025 | Rytary, Crexont |
| Amgen INC. | $184.04 | 2019-2024 | Uplizna |
| Biohaven Pharmaceutical Holding Company Ltd. | $165.80 | 2022 | |
| Medtronic, INC. | $138.32 | 2023-2025 | Percept Pc Brainsense |
| Sk Life Science, INC. | $125.00 | 2021 | |
| Ucb, INC. | $123.22 | 2021-2025 | Rystiggo, Zilbrysq |
| Neurelis, INC. | $92.21 | 2021-2022 | |
| Boston Scientific Corporation | $71.67 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $63.72 | 2024 | Neurostar Tms Therapy System |
| Arbor Pharmaceuticals, INC. | $50.04 | 2020-2022 | |
| Csl Behring | $46.80 | 2024-2025 | Hizentra |
| Impel Pharmaceuticals INC. | $45.14 | 2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $45.12 | 2021-2023 | Ingrezza, Ongentys |
| Scilex Pharmaceuticals INC. | $39.15 | 2022-2025 | |
| Argenx US, INC. | $34.05 | 2025 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $33.12 | 2019-2020 | |
| Genzyme Corporation | $31.99 | 2022 | |
| Inspire Medical Systems, INC. | $29.36 | 2025 | Inspire |
| Biogen, INC. | $27.77 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $25.76 | 2023 | Rexulti |
| Genentech USA, INC. | $23.90 | 2025 | Ocrevus Zunovo |
| Xeris Pharmaceuticals, INC. | $23.12 | 2023 | Keveyis |
| Ipsen Biopharmaceuticals, INC | $23.04 | 2025 | Dysport |
| Biohaven Pharmaceuticals, INC. | $20.00 | 2020 | |
| Harmony Biosciences LLC | $17.13 | 2021 | |
| Medtronic USA, INC. | $16.68 | 2019 | |
| Impel Pharmaceuticals LLC | $15.93 | 2025 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $13.17 | 2020 | |
| Currax Pharmaceuticals LLC | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clair Cascella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.